• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Concurrent lung and liver ablation proves feasible

Article

Interventional radiologists in Italy have shown the feasibility of concurrent radio-frequency ablation of hepatic and pulmonary tumors.

Interventional radiologists in Italy have shown the feasibility of concurrent radio-frequency ablation of hepatic and pulmonary tumors.

Dr. Davide Becanni and colleagues at the University of Florence performed 65 RF ablations in 25 patients with hepatic and pulmonary metastases from colorectal carcinoma. Both hepatic and pulmonary lesions were treated in a single-session procedure using one RF generator with either single or cluster probes. RFA successfully ablated all lesions, as confirmed by either CT or PET follow-up.

No liver complications were reported, although five patients who were treated for pulmonary metastases developed pneumothorax.

Physicians still have to define the best target population and the cost-benefit ratio for dual RFA. But his study shows that the procedure can reduce hospitalization time without adding to the complication rate, Becanni said.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.